Richard Glynne joined Inception as CSO in 2018. Richard joined Inception after leading search and evaluation for immune oncology, immunology and digital therapeutics in the business development group at Novartis. Prior to the BD role, Richard served as an Executive Director, leading a research group at the Genomics Institute of the Novartis Research Foundation, that focused on infectious disease and immunology and contributed to multiple pre-clinical and clinical development programs. Richard trained in immunology and genetics during his PhD (ICRF, London) and post-doc (HHMI, Stanford), after which he held leadership positions in Eos Biotechnology and Phenomix Corporation, before joining Novartis in 2004.

Don Hertzog joined Inception as Head of Chemistry in 2022 after serving as a Senior Research Fellow at Enveda Therapeutics and leading the chemistry departments at both Ribometrix, Inc. and HemoShear Therapeutics, as well as the Early Lead Discovery team at Abide Therapeutics. Prior to moving into biotech, Don held a variety of leadership positions at both Bayer and GlaxoSmithKline (GSK), during which time Don and his teams identified multiple clinical development compounds. Don brings expertise in all aspects of drug discovery from early lead identification through clinical candidate selection. Don obtained PhD with Albert Padwa at Emory University and then completed an NIH-sponsored postdoctoral fellowship in medicinal chemistry with Dale Boger at the Scripps Research Institute.

Rich brings 20 years of financial experience, having most recently served as CFO of Samsara Biocapital. There, he was responsible for the firm’s financial operations, as well as business management, compliance and investor relations. Before Samsara, he was CFO and COO of Pacific Grove Capital, and prior to that held similar roles at Marcato Capital and Cannell Capital. Rich graduated from the University of San Francisco with a B.S. in Finance and earned a Graduate Certificate in Tax from Golden Gate University. He is a member of the Dean’s Circle at the University of San Francisco School of Business Management.

Cathy Dring started working with Versant in December 2012 as legal counsel. She has more than 25 years experience as a venture capital attorney. Cathy received her J.D. from the USC Gould School of Law and practiced in the corporate group at Pillsbury Winthrop and was in the Venture Capital group at Cooley LLP for more than 10 years. Prior to working with Versant, she provided legal consulting services to several venture capital funds. Cathy received her B.S. from UCSD in Biophysics.